Company / Free Cash Flow
Theravance Biopharma, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$238.5M
FY2025
5-year range
-$257.0M / $238.5M
FY2021-FY2025
Trend
+2109.8%
vs FY2024
Sector context
#32 of 194
Health Care
What the data says
Free Cash Flow changed +2110% YoY in FY2025, a notable deviation from the 9-year average annual change of +231%.
Based on SEC 10-K filings.
$238M in FY2025. Top quartile in the Health Care sector.
Improved from -$29M to $238M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 194This company $238.5M Sector average $470.6M
▼
-49.3% below sector average
Key checks
Key Insights
- Theravance Biopharma, Inc.'s free cash flow has grown for 3 consecutive years.
- In FY2025, free cash flow increased 2109.8% year-over-year.
- Ranks #32 out of 194 companies in the Health Care sector.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $238.5M | +2109.8% |
| FY2024 | -$11.9M | +59.8% |
| FY2023 | -$29.5M | +88.5% |
| FY2022 | -$257.0M | -21.7% |
| FY2021 | -$211.3M | +17.8% |
| FY2020 | -$257.0M | -26.3% |
| FY2019 | -$203.5M | -101.2% |
| FY2018 | -$101.1M | +50.3% |
| FY2017 | -$203.5M | -101.2% |
| FY2016 | -$101.1M | +18.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026